LIPTRUZET
Total Payments
$42,131
Transactions
33
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $5,921 | 10 | 2 |
| 2017 | $36,210 | 23 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $27,523 | 24 | 65.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,450 | 1 | 34.3% |
| Food and Beverage | $158.31 | 8 | 0.4% |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $42,131
Product Information
- Type Drug
- Total Payments $42,131
- Total Doctors 4
- Transactions 33
About LIPTRUZET
LIPTRUZET is a drug associated with $42,131 in payments to 4 healthcare providers, recorded across 33 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $5,921 was paid across 10 transactions to 2 doctors.
The most common payment nature for LIPTRUZET is "Travel and Lodging" ($27,523, 65.3% of total).